Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32281
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chmielecki, Juliann | - |
dc.contributor.author | Mok, Tony | - |
dc.contributor.author | Wu, Yi-Long | - |
dc.contributor.author | Han, Ji-Youn | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.contributor.author | Ramalingam, Suresh S | - |
dc.contributor.author | John, Thomas | - |
dc.contributor.author | Okamoto, Isamu | - |
dc.contributor.author | Yang, James Chih-Hsin | - |
dc.contributor.author | Shepherd, Frances A | - |
dc.contributor.author | Bulusu, Krishna C | - |
dc.contributor.author | Laus, Gianluca | - |
dc.contributor.author | Collins, Barbara | - |
dc.contributor.author | Barrett, J Carl | - |
dc.contributor.author | Hartmaier, Ryan J | - |
dc.contributor.author | Papadimitrakopoulou, Vassiliki | - |
dc.date | 2023 | - |
dc.date.accessioned | 2023-03-08T01:06:46Z | - |
dc.date.available | 2023-03-08T01:06:46Z | - |
dc.date.issued | 2023-02-27 | - |
dc.identifier.citation | Nature Communications 2023; 14(1) | en_US |
dc.identifier.issn | 2041-1723 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/32281 | - |
dc.description.abstract | Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. This analysis evaluates acquired resistance mechanisms to second-line osimertinib (nā=ā78) in patients with EGFR T790M advanced non-small cell lung cancer (NSCLC) from AURA3 (NCT02151981), a randomized phase 3 study comparing osimertinib with chemotherapy. Plasma samples collected at baseline and disease progression/treatment discontinuation are analyzed using next-generation sequencing. Half (50%) of patients have undetectable plasma EGFR T790M at disease progression and/or treatment discontinuation. Fifteen patients (19%) have >1 resistance-related genomic alteration; MET amplification (14/78, 18%) and EGFR C797X mutation (14/78, 18%). | en_US |
dc.language.iso | eng | - |
dc.title | Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Nature Communications | en_US |
dc.identifier.affiliation | Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA. | en_US |
dc.identifier.affiliation | State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China. | en_US |
dc.identifier.affiliation | Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China. | en_US |
dc.identifier.affiliation | Center for Lung Cancer, National Cancer Center, Goyang, Republic of Korea. | en_US |
dc.identifier.affiliation | Section of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. | en_US |
dc.identifier.affiliation | Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. | en_US |
dc.identifier.affiliation | Medical Oncology, Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, VIC, Australia. | en_US |
dc.identifier.affiliation | Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. | en_US |
dc.identifier.affiliation | Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. | en_US |
dc.identifier.affiliation | Departments of Medical Oncology and Hematology, Princess Margaret Cancer Centre, and the University of Toronto, Toronto, ON, Canada. | en_US |
dc.identifier.affiliation | Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK. | en_US |
dc.identifier.affiliation | Biometrics and Information Sciences, AstraZeneca, Cambridge, UK. | en_US |
dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute | en_US |
dc.identifier.affiliation | Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA. | en_US |
dc.identifier.affiliation | Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. vpapadimitrakopoulou@gmail.com. | en_US |
dc.identifier.doi | 10.1038/s41467-023-35962-x | en_US |
dc.type.content | Text | en_US |
dc.identifier.orcid | 0000-0002-3611-0258 | en_US |
dc.identifier.orcid | 0000-0001-5033-0006 | en_US |
dc.identifier.orcid | 0000-0002-0757-3106 | en_US |
dc.identifier.orcid | 0000-0003-3399-5342 | en_US |
dc.identifier.orcid | 0000-0002-5092-6640 | en_US |
dc.identifier.orcid | 0000-0001-7416-6036 | en_US |
dc.identifier.orcid | 0000-0003-3172-1399 | en_US |
dc.identifier.pubmedid | 36849516 | - |
dc.description.volume | 14 | - |
dc.description.issue | 1 | - |
dc.description.startpage | 1071 | - |
dc.subject.meshtermssecondary | Carcinoma, Non-Small-Cell Lung/drug therapy | - |
dc.subject.meshtermssecondary | Carcinoma, Non-Small-Cell Lung/genetics | - |
dc.subject.meshtermssecondary | ErbB Receptors/genetics | - |
dc.subject.meshtermssecondary | Lung Neoplasms/drug therapy | - |
dc.subject.meshtermssecondary | Lung Neoplasms/genetics | - |
dc.subject.meshtermssecondary | Protein Kinase Inhibitors/pharmacology | - |
dc.subject.meshtermssecondary | Protein Kinase Inhibitors/therapeutic use | - |
local.name.researcher | John, Thomas | |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.